Top Markets
#1 Lisk Lisk +32.65%
#2 Derive Derive +27.70%
#3 ROLL ROLL +27.26%
#4 Asteroid Shiba Asteroid Shiba +20.38%
#5 MarsCoin MarsCoin +18.51%
#6 Cortex Cortex +15.31%
#7 龙虾 (Lobster) 龙虾 (Lobster) +15.29%
#8 Synapse Synapse +14.12%
#9 AUKI AUKI +14.03%
#10 IOST IOST +13.63%
Coin of the day
Lisk Lisk
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Eli Lilly and Company Eli Lilly and Company

Eli Lilly and Company

LLY
Rang în acțiuni #14
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to... Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Preț acțiune
$1,133.97
Ultima sincronizare: 2026-09-15
Capitalizare de piață
$1.068T
Schimbare (1 zi)
-0.39%
Schimbare (1 an)
48.29%
Țară
US
Tranzacționează Eli Lilly and Company (LLY)

Categorie

Healthcare
Număr de acțiuni în circulație pentru Eli Lilly and Company (LLY)
Număr de acțiuni în circulație la data de June 2026: 892.40M
Conform celor mai recente rapoarte financiare și prețului acțiunilor Eli Lilly and Company, numărul curent de acțiuni în circulație este 892.40M. La sfârșitul anului December 2024, compania avea 900.61M acțiuni în circulație. Numărul de acțiuni în circulație este de obicei influențat de splituri de acțiuni și programe de răscumpărare.
Istoricul acțiunilor în circulație pentru Eli Lilly and Company (LLY) din 2000 până în 2026
Acțiuni în circulație la sfârșitul fiecărui an
An Acțiuni în circulație Schimbă
2026 (TTM) 892.40M -0.62%
2025 898.00M -0.29%
2024 900.61M 0.14%
2023 899.38M -5.35%
2022 950.18M -0.36%
2021 953.65M -0.31%
2020 956.59M -0.10%
2019 957.53M -6.83%
2018 1.03B -2.31%
2017 1.05B -4.44%
2016 1.10B -0.40%
2015 1.11B -0.48%
2014 1.11B -0.55%
2013 1.12B -2.59%
2012 1.15B 2.92%
2011 1.11B 0.74%
2010 1.11B 0.68%
2009 1.10B 0.35%
2008 1.09B 0.37%
2007 1.09B 0.33%
2006 1.09B -0.08%
2005 1.09B 0.35%
2004 1.08B 0.74%
2003 1.08B -0.27%
2002 1.08B 0.12%
2001 1.08B -0.28%
2000 1.08B 0.00%
Acțiuni în circulație pentru companii similare sau concurente
Companie Acțiuni în circulație Diferență Țara
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 2.44B 173.44%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 1.77B 98.45%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 796.00M -10.80%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 0.00 -100.00%
US
Novartis AG Novartis AG
Novartis AG
NOVN.SW
 1.91B 114.37%
CH